Skip to main content
Top
Published in: Rheumatology International 6/2021

01-06-2021 | Ultrasound | Observational Research

Is it possible to not perform salivary gland biopsy in targeted patients according to unstimulated salivary flow results in patients with suspected Sjögren's syndrome?

Authors: Agata Sebastian, Patryk Woytala, Marta Madej, Krzysztof Proc, Katarzyna Czesak-Woytala, Maciej Sebastian, Krzysztof Zub, Piotr Wiland

Published in: Rheumatology International | Issue 6/2021

Login to get access

Abstract

Introduction/objective

Xerostomia is one of the main symptoms of primary Sjögren's syndrome (pSS). The unstimulated salivary flow (UWS) test is one of the objective Sjögren's syndrome classification criteria used to assess xerostomia's severity. The study’s objective was to evaluate UWS rate measurements (with a threshold rate of 0.1 mL/min) in the screening of patients suspected with pSS, presenting with xerostomia in whom labial salivary gland biopsy (LSGB) should be performed. We will try to answer whether it is possible not to perform LSGB in targeted patients according to UWS results? We analyze the correlation between UWS value and focus score (FS) and anti-SSA antibodies.

Methods

The study group consisted of subjects above 18 years of age with a subjective feeling of oral dryness.

Results

A total of 105 subjects were qualified for the study. The final diagnosis of pSS was made in 44 patients according to the classification criteria from 2016. No age differences were identified between pSS patients and control group subjects (patients with dry mouth without autoimmune background). UWS rates were significantly lower in pSS patients than in the control group. No association was identified between UWS and focus score (FS) ≥ 1 in LSGB. No differences were observed between anti-SSA-positive and anti-SSA-negative patients in terms of age, UWS rates, FS.

Conclusion

LSGB should be performed in all suspected pSS cases regardless of the UWS rate value, particularly in subjects without specific anti-SSA antibodies. In patients with suspected pSS, only less than one-half of the UWS measurements are below the value of 0.1 mL/min adopted as the threshold in the classification criteria for pSS.
Literature
1.
go back to reference Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. ArthritisRheumatol 69:35–45. https://doi.org/10.1002/art.39859CrossRef Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. ArthritisRheumatol 69:35–45. https://​doi.​org/​10.​1002/​art.​39859CrossRef
14.
go back to reference Haga HJ (2002) Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren’s syndrome. J Rheumatol. 29(2):305–308PubMed Haga HJ (2002) Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren’s syndrome. J Rheumatol. 29(2):305–308PubMed
17.
go back to reference Daniels TE, Cox D, Shiboski CH et al (2011) Sjogren’s International Collaborative Clinical Alliance Research Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren’s syndrome among 1,726 registry participants. Arthritis Rheum 63:2021–2030CrossRef Daniels TE, Cox D, Shiboski CH et al (2011) Sjogren’s International Collaborative Clinical Alliance Research Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren’s syndrome among 1,726 registry participants. Arthritis Rheum 63:2021–2030CrossRef
Metadata
Title
Is it possible to not perform salivary gland biopsy in targeted patients according to unstimulated salivary flow results in patients with suspected Sjögren's syndrome?
Authors
Agata Sebastian
Patryk Woytala
Marta Madej
Krzysztof Proc
Katarzyna Czesak-Woytala
Maciej Sebastian
Krzysztof Zub
Piotr Wiland
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-04840-4

Other articles of this Issue 6/2021

Rheumatology International 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.